Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5245-5250

  Kim, Su Jung ^a   Han, Sae Won ^a   Oh, Do Youn ^a   Yi, Nam Joon ^b   Kim, Yoon Jun ^a   Im, Seock Ah ^a   Yoon, Jung Hwan ^a   Kang, Gyeong Hoon ^b   Suh, Kyung Suk ^b   Bang, Yung Jue ^a,c   Jang, Ja Joon ^b   Kim, Tae You ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Platinum; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; RETROSPECTIVE STUDIES; TEGAFUR; TUMOR MARKERS, BIOLOGICAL;

EID: 78751514082     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N and Ducreux M: Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97: 862-7, 2007.
5. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY and Bang YJ: Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 20: 1402-1407, 2009.
6. Shim JH, Park JW, Nam BH, Lee WJ and Kim CM: Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 63: 459-67, 2009.
7. Naguib FN, el Kouni MH and Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985.
8. Jiang W, Lu Z, He Y and Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 5: 395-399, 1997.
9. Ikeguchi M, Hirooka Y, Makino M and Kaibara N: Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. Oncol Rep 5: 621-625, 2001.
10. Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39: 2-15, 2009.
11. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15: 85-106, 2004.
12. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
14. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ and Kim NK: Biomarker analysis in stage III-IV (MO) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100: 732-738, 2009.
15. Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, Wada H, Noda T, Dono K, Umeshita K and Monden M: Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 112: 1765-1771, 2008.
16. Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y and Chung H: Combination therapy with S-I and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology 75(Suppl 1): 106-113, 2008.
17. Sakamoto S, Taga H, Uchikoshi T, Kudo H, Suzuki S, Sugiura Y, Kuwa K and Endo Y: Synergistic effect of oral UFT in combination with cisplatin on DNA synthesis in rat hepatocarcinomas. Anticancer Res 13: 631-634, 1993.
18. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K and Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 23: 1891-1897, 2003.
19. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A and Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005.
20. Milano G and Chamorey AL: Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19: 177-189, 2002. (Pubitemid 34310826)
21. Yokoyama I, Carr B, Saitsu H, Iwatsuki S and Starzl TE: Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 65: 2095-2100, 1991.
22. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY and Bang YJ: Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 24: 800-805, 2009.